HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Hemasphere. 2020 Jan 3;4(1):e325.
doi: 10.1097/HS9.0000000000000325.
eCollection 2020 Feb.
1 Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
2 HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
3 Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
4 Department of Hematology, Amsterdam UMC, VU MC, Amsterdam, The Netherlands.
5 Department of Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
6 Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands.
7 Department of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany.
8 Department of Internal Medicine, Tergooi Hospital, Hilversum, The Netherlands.
9 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
10 Manchester Cancer Research Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom.
11 Department of Medicine III, University hospital, LMU Munich, Germany.
12 Department of Pathology, Amsterdam UMC, VU MC, Amsterdam, The Netherlands.
13 Department of Hematology, Amsterdam UMC, University of Amsterdam and Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands.